FY2025 EPS Estimate for Haemonetics Decreased by Analyst

Haemonetics Co. (NYSE:HAE) – Equities researchers at Zacks Research dropped their FY2025 earnings per share estimates for shares of Haemonetics in a research report issued to clients and investors on Thursday, March 13th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings of $4.54 per share for the year, down from their prior estimate of $4.56. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q4 2025 earnings at $1.21 EPS, Q1 2026 earnings at $1.11 EPS, Q2 2026 earnings at $1.22 EPS, Q3 2026 earnings at $1.34 EPS, Q4 2026 earnings at $1.34 EPS, FY2026 earnings at $5.00 EPS, Q1 2027 earnings at $1.37 EPS and FY2027 earnings at $5.73 EPS.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%.

A number of other research firms also recently issued reports on HAE. Needham & Company LLC decreased their price objective on shares of Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a report on Friday, February 7th. JPMorgan Chase & Co. began coverage on shares of Haemonetics in a research note on Friday, December 6th. They set an “overweight” rating and a $116.00 price target for the company. Barrington Research dropped their price objective on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Raymond James reissued a “strong-buy” rating and issued a $115.00 target price (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Finally, StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $101.67.

Haemonetics Trading Down 0.3 %

Shares of Haemonetics stock opened at $65.76 on Monday. The firm has a market cap of $3.30 billion, a PE ratio of 25.89, a P/E/G ratio of 1.11 and a beta of 0.43. Haemonetics has a 1 year low of $58.80 and a 1 year high of $97.97. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The stock has a fifty day moving average price of $68.61 and a 200-day moving average price of $75.41.

Institutional Trading of Haemonetics

Institutional investors have recently added to or reduced their stakes in the business. Global Alpha Capital Management Ltd. purchased a new stake in Haemonetics during the 3rd quarter valued at about $806,000. Loomis Sayles & Co. L P increased its stake in shares of Haemonetics by 8.1% in the third quarter. Loomis Sayles & Co. L P now owns 163,856 shares of the medical instruments supplier’s stock worth $13,171,000 after buying an additional 12,310 shares during the period. BNP Paribas Financial Markets raised its holdings in Haemonetics by 174.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier’s stock valued at $1,362,000 after buying an additional 10,774 shares during the last quarter. Westfield Capital Management Co. LP boosted its position in Haemonetics by 10.9% during the 3rd quarter. Westfield Capital Management Co. LP now owns 823,663 shares of the medical instruments supplier’s stock valued at $66,206,000 after buying an additional 80,783 shares during the period. Finally, Boston Trust Walden Corp grew its stake in shares of Haemonetics by 13.1% in the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock worth $71,500,000 after purchasing an additional 106,114 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.